On the public citation graph
Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial
0 signed · 68 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/archinternmed.2007.37openalex-snapshot
Development and Validation of a Prognostic Index for Health Outcomes in Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1016/j.jval.2010.09.011openalex-snapshot
Predicting EQ-5D Values Using the SGRQ
inferredcites →https://doi.org/10.1016/j.jval.2011.06.008openalex-snapshot
Developing and Applying a Stochastic Dynamic Population Model for Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1016/j.jval.2014.03.1721openalex-snapshot
Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease: Cross-Model Comparison of Hypothetical Treatment Scenarios
inferredcites →https://doi.org/10.1016/j.jval.2014.08.1852openalex-snapshot
Validating A Model To Predict Disease Progression Outcomes In Patients With COPD
inferredcites →https://doi.org/10.1016/j.jval.2016.10.016openalex-snapshot
External Validation of Health Economic Decision Models for Chronic Obstructive Pulmonary Disease (COPD): Report of the Third COPD Modeling Meeting
inferredcites →https://doi.org/10.1016/j.rmed.2018.10.024openalex-snapshot
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective
inferredcites →https://doi.org/10.1016/j.yrmex.2019.100008openalex-snapshot
Cost-effectiveness analysis of a single-inhaler triple therapy for patients with advanced chronic obstructive pulmonary disease (COPD) using the FULFIL trial: A UK perspective
inferredcites →https://doi.org/10.1056/nejmoa021322openalex-snapshot
The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1056/nejmoa063070openalex-snapshot
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1056/nejmoa1713901openalex-snapshot
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
inferredcites →https://doi.org/10.1080/24745332.2017.1395588openalex-snapshot
CTS position statement: Pharmacotherapy in patients with COPD—An update
inferredcites →https://doi.org/10.1093/aje/kww085openalex-snapshot
The Association Between Rate and Severity of Exacerbations in Chronic Obstructive Pulmonary Disease: An Application of a Joint Frailty-Logistic Model
inferredcites →https://doi.org/10.1097/00008483-200207000-00004openalex-snapshot
Global Initiative for Chronic Obstructive Lung Disease
inferredcites →https://doi.org/10.1164/rccm.200703-456soopenalex-snapshot
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1164/rccm.201204-0596ppopenalex-snapshot
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1177/0272989x15610781openalex-snapshot
Statistical Modeling of Disease Progression for Chronic Obstructive Pulmonary Disease Using Data from the ECLIPSE Study
inferredcites →https://doi.org/10.1177/0272989x16653118openalex-snapshot
Development of the Galaxy Chronic Obstructive Pulmonary Disease (COPD) Model Using Data from ECLIPSE: Internal Validation of a Linked-Equations Cohort Model
inferredcites →https://doi.org/10.1177/0272989x16662009openalex-snapshot
Development of a Conceptual Model of Disease Progression for Use in Economic Modeling of Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.1183/090319openalex-snapshot
An integrated model involving sleep units and primary care for the diagnosis of sleep apnoea
inferredcites →https://doi.org/10.1183/09031936.00111707openalex-snapshot
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)
inferredcites →https://doi.org/10.1183/09031936.00125612openalex-snapshot
Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification
inferredcites →https://doi.org/10.1183/13993003.congress-2018.pa1991openalex-snapshot
Risk of exacerbation and pneumonia with single inhaler triple versus dual therapy in IMPACT
inferredcites →https://doi.org/10.1186/1465-9921-11-122openalex-snapshot
Characterisation of COPD heterogeneity in the ECLIPSE cohort
inferredcites →https://doi.org/10.1186/s13104-015-1427-yopenalex-snapshot
Clinical, humanistic, and economic burden of chronic obstructive pulmonary disease (COPD) in Canada: a systematic review
inferredcites →https://doi.org/10.1378/chestopenalex-snapshot
Clinical differences between patients with COPD due to biomass smoke or tobacco
inferredcites →https://doi.org/10.1378/chest.130.4.1117openalex-snapshot
Does Quality of Life of COPD Patients as Measured by the Generic EuroQol Five-Dimension Questionnaire Differentiate Between COPD Severity Stages?
inferredcites →https://doi.org/10.1513/annalsats.202002-096ocopenalex-snapshot
Risk of Exacerbation and Pneumonia with Single-Inhaler Triple versus Dual Therapy in IMPACT
inferredcites →https://doi.org/10.2147/copd.s173901openalex-snapshot
When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals
inferredcites →https://doi.org/10.2147/copd.s221980openalex-snapshot
Evaluating Patient Preferences of Maintenance Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Discrete Choice Experiment in the UK, USA and Germany
inferredcites →https://doi.org/10.2165/00019053-200523060-00008openalex-snapshot
Development of an Economic Model to Assess the Cost Effectiveness of Treatment Interventions for Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.2165/11590380-000000000-00000openalex-snapshot
Cost Effectiveness of Budesonide/Formoterol Added to Tiotropium Bromide versus Placebo Added to Tiotropium Bromide in Patients with Chronic Obstructive Pulmonary Disease
inferredcites →https://doi.org/10.5588/ijtld.15.0472openalex-snapshot
The global economic burden of asthma and chronic obstructive pulmonary disease
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.3863358openalex-extracted
A Benefit-Harm Analysis of Azithromycin for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
inferred← citeshttps://doi.org/10.1007/s40258-022-00732-1openalex-snapshot
Economic Evaluation of Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate for the Treatment of Moderate to Very Severe Chronic Obstructive Pulmonary Disease in China Using a Semi-Markov Model
inferred← citeshttps://doi.org/10.1016/j.chest.2022.11.027openalex-snapshot
Comparison of Clinical Outcomes Among Different Fixed-Dose Combinations of Long-Acting Muscarinic Antagonists and Long-Acting β2-Agonists in Patients With COPD
inferred← citeshttps://doi.org/10.1016/j.rmed.2018.10.024openalex-snapshot
Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective
inferred← citeshttps://doi.org/10.1016/j.rmed.2022.106807openalex-snapshot
Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study
inferred← citeshttps://doi.org/10.1016/j.rmed.2024.107632openalex-snapshot
Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China
inferred← citeshttps://doi.org/10.1016/j.rmed.2024.107694openalex-snapshot
The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada – The IMPACT trial
inferred← citeshttps://doi.org/10.1016/j.semerg.2021.08.001openalex-snapshot
Revisión narrativa de la terapia inhalatoria en la EPOC
inferred← citeshttps://doi.org/10.1080/14656566.2021.1873953openalex-snapshot
Economic evaluations of chronic obstructive pulmonary disease pharmacotherapy: how well are the real-world issues of medication adherence, comorbidities and adverse drug-reactions addressed?
inferred← citeshttps://doi.org/10.1080/14737167.2025.2603950openalex-snapshot
Optimizing COPD management in Latin America: a cost-effectiveness analysis of FF/UMEC/VI in Colombia
inferred← citeshttps://doi.org/10.1080/14737167.2026.2693168openalex-snapshot
Single versus multiple inhaler triple therapy in COPD using data from the pragmatic INTREPID trial: cost-effectiveness analysis from the Chilean public healthcare system perspective
inferred← citeshttps://doi.org/10.1080/17476348.2022.2145951openalex-snapshot
Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: a systematic literature review
inferred← citeshttps://doi.org/10.1080/17476348.2025.2582249openalex-snapshot
Is dual bronchodilation a cost-effective alternative to ICS/LABA in COPD? A Colombian healthcare system evaluation
inferred← citeshttps://doi.org/10.1080/17512433.2022.2071700openalex-snapshot
A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD
inferred← citeshttps://doi.org/10.1080/24745332.2023.2289890openalex-snapshot
Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate dihydrate compared with dual therapy for the treatment of chronic obstructive pulmonary disease (COPD) in Canada
inferred← citeshttps://doi.org/10.1136/thoraxjnl-2021-217962openalex-snapshot
Benefit–harm analysis of azithromycin for the prevention of acute exacerbations of chronic obstructive pulmonary disease
inferred← citeshttps://doi.org/10.1183/23120541.00333-2021openalex-snapshot
Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial
inferred← citeshttps://doi.org/10.1186/s12913-022-08640-9openalex-snapshot
Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region
inferred← citeshttps://doi.org/10.1186/s12931-023-02523-1openalex-snapshot
Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
inferred← citeshttps://doi.org/10.15326/jcopdf.2021.0261openalex-snapshot
Designing Clinical Trials in “Regular” COPD Versus Alpha-1 Antitrypsin Deficiency-Associated COPD: “More Alike Than Unalike?”
inferred← citeshttps://doi.org/10.17925/usprd.2020.5.1.18openalex-snapshot
Triple Combination Inhalers in Chronic Obstructive Pulmonary Disease and Asthma
inferred← citeshttps://doi.org/10.2147/copd.s312853openalex-snapshot
Quantifying the Economic Impact of Delayed Multiple-Inhaler Triple Therapy Initiation in Patients with COPD: A Retrospective Cohort Study of Linked Electronic Medical Record and Hospital Administrative Data in England
inferred← citeshttps://doi.org/10.2147/copd.s331636openalex-snapshot
Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model
inferred← citeshttps://doi.org/10.2147/copd.s342244openalex-snapshot
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial
inferred← citeshttps://doi.org/10.2147/copd.s366765openalex-snapshot
Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial
inferred← citeshttps://doi.org/10.2147/copd.s370577openalex-snapshot
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial
inferred← citeshttps://doi.org/10.2147/copd.s400707openalex-snapshot
Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
inferred← citeshttps://doi.org/10.2147/copd.s423993openalex-snapshot
Real-World Disease Burden and Healthcare Resource Utilization Among Patients with COPD and Asthma Using Triple Therapy (FF/UMEC/VI) in the United States
inferred← citeshttps://doi.org/10.2147/copd.s475748openalex-snapshot
Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK
inferred← citeshttps://doi.org/10.2147/copd.s492524openalex-snapshot
Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective
inferred← citeshttps://doi.org/10.30789/rcneumologia.v35.n2supl-1.2023.984openalex-snapshot
Guía de práctica clínica sobre el diagnóstico, manejo y seguimiento de la enfermedad pulmonar obstructiva crónica en Colombia 2023
inferred← citeshttps://doi.org/10.3390/life12020173openalex-snapshot
The Impact of 52-Week Single Inhaler Device Triple Therapy versus Dual Therapy on the Mortality of COPD Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
inferred← citeshttps://doi.org/10.5005/jp-journals-11010-1126openalex-snapshot
Effectiveness, Utility, and Economic Analysis of Three-drug Treatment vs Two-drug Treatment in Chronic Obstructive Pulmonary Disease Patients
inferred← citeshttps://doi.org/10.6084/m9.figshare.24196726openalex-snapshot
Additional file 1 of Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
inferred← citeshttps://doi.org/10.7324/japs.2021.110916openalex-snapshot
Meta-analysis of cost-effectiveness of three-drug therapy versus two-drug therapy in chronic obstructive pulmonary disease patients
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.